Dr. Yihan Wang's team is selected as the Fifth Batch of Key Overseas Chinese Entrepreneurial Teams by the Overseas Chinese Affairs Office of the State Council of China
The team of Dr. Yihan Wang, Chairman and General Manager of Shenzhen TargetRx Inc., was selected as the Fifth Batch of Key Overseas Chinese Entrepreneurial Teams by the Overseas Chinese Affairs Office of the State Council of China. In addition, Dr. Wang was elected as a member of the Science and Technology Innovation Committee of the China Federation of Overseas Chinese Entrepreneurs, and he is participating in the 2017 Annual Meeting of the Science and Technology Innovation Committee of the China Federation of Overseas Chinese Entrepreneurs in Ningbo.
Δ A group photo of Dr. Yihan Wang with Yuanping Qiu, Director of the Overseas Chinese Affairs Office of the State Council
The “Key Overseas Chinese Entrepreneurship Team” is an innovative measure implemented by the Overseas Chinese Affairs Office of the State Council, and aims to increase support for outstanding overseas Chinese entrepreneurship teams, encourage and promote overseas Chinese teams to return to China for entrepreneurship, and promote national and regional scientific, technological and economic development. The 100 key overseas Chinese entrepreneurship teams identified in this selection are engaged in industries that cover energy conservation and environmental protection, new-generation information technology, biomedicine, high-end equipment manufacturing and other strategic emerging industries supported by China.
Δ 2017 Annual Meeting of the Science and Technology Innovation Committee of the China Federation of Overseas Chinese Entrepreneurs
Dr. Yihan Wang’s team for R&D of Class 1.1 targeted anti-cancer small molecule drugs was selected for the project of development and clinical study of Class 1.1 targeted small molecule drugs for the acquired drug resistance of lung cancer. In response to the problem of acquired drug resistance in non-small cell lung cancer, the project strives to develop the third-generation epithelial growth factor receptor (EGFR) inhibitor with new structure, high efficiency, high selectivity, and good safety. The new drug development stage of the project has been completed, 4 domestic invention patents and 3 international invention patents have been applied for, and the pre-clinical candidate TGR-360 has been determined. Through pre-clinical biological data validation, TGR-360 has high activity and high selectivity at the molecular level, cellular level, organ level and animal level, which is significantly better than similar national and international products; in in vitro metabolism evaluation and animal metabolism evaluation, TGR-360 shows excellent druggability. In the next 5 years, the pre-clinical study, IND application and clinical study on TGR-360 will be completed. The research direction of Dr. Yihan Wang’s team is to independently develop the third-generation EGFR inhibitor with a new structure and intellectual property rights. This inhibitor can solve the acquired drug resistance caused by the T790M mutation, bringing new hope for Chinese lung cancer patients with a high incidence of EGFR mutations.
Δ Group photo of the members of the Science and Technology Innovation Committee of the Chinese Federation of Overseas Chinese Entrepreneurs
Dr. Yihan Wang returned to China in 2014 and founded Shenzhen TargetRx Inc. The company is located in the high-tech incubation base of Shenzhen Nanshan Science and Technology Park. At the beginning of its establishment, it has received investment from well-known domestic angel agents. TargetRx focuses on the R&D of international cutting-edge targeted new drugs, and strives to become the world’s leading R&D base of targeted new drugs.
Δ Some laboratories of TargetRx
At this stage, TargetRx has completed the construction of the company's core technology platform and innovative drug early R&D team, and has successfully developed a variety of first-in-class drugs. So far, it has applied for 48 invention patents, including 29 Chinese invention patents and 19 PCT invention patents. The company developed three anti-cancer first-in-class products for the treatment of EGFR-mutated lung cancer, ALK-mutated lung cancer, and leukemia, respectively.
Δ TargetRx Data Cloud Platform
Being selected into the key overseas Chinese entrepreneurship team is not only an affirmation of TargetRx, but also an incentive for TargetRx's unswerving belief in making new drugs with independent intellectual property rights. It is the ideal of every TargetRx staff to make good drugs and make China's own drugs. I believe that under the leadership of Dr. Yihan Wang, TargetRx will be able to develop new drugs that benefit cancer patients and contribute to the human health.